Teva intros generic Actonel

JERUSALEM — Teva announced Monday that it had launched its generic version of Actonel (risedronate sodium) in 5-, 30- and 35-mg dosage strengths. Teva’s generic will have 180 days of market exclusivity because the company was the first to file for approval from the Food and Drug Administration. 

 

Actonel is meant for the treatment or prevention of osteoporosis in post-menopausal women, increase bone mass or treat osteoporosis in men or women on a corticosteroid. It can also be used to treat Paget’s disease of the bone.